(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Online

Complimentary - Innovative Strategies for Developing Safer Cancer Therapies

Overview


 

This Solution Provider Webinar is brought to you by DIA in cooperation with BioClinica.

Within oncology drug development, sponsors face the challenge of effectively evaluating potential cardiovascular toxicity. The emerging clinical discipline of ‘Cardio-Oncology’ (CO) aims to promote safer drugs and better outcomes for cancer patients through the use of multimodal strategies for assessing drug dependent cardiac abnormalities. In this webinar, experts will highlight state-of-the-art approaches and key considerations for establishing successful cardiovascular safety strategies for oncology clinical trials. The webinar will provide an overview of the emerging CO discipline and will feature a case study highlighting the design and innovative cardiovascular imaging methodologies used to detect and monitor cardiovascular safety for a recent FDA approved Multiple Myeloma drug.

TO REGISTER FOR THIS EVENT PLEASE CLICK HERE

Featured topics

  • Current perspectives, strategies and considerations for assessing the cardiovascular safety of oncology compounds
  • Advances in multimodal approaches including Echocardiography and strain imaging for detecting cardiac dysfunction
  • Pharma case study highlighting the design and methodology of a cardiovascular safety study for the FDA approved oncology drug carfilzomib

Who should attend?

Industry professionals within biopharmaceutical companies involved in following areas:

  • CV safety and risk
  • Cardiovascular
  • Oncology
  • Cardiology
  • Clinical program management
  • Clinical affairs
  • Clinical studies
  • Regulatory affairs
  • Pharmacology
  • Clinical research
  • Clinical operations
  • Safety surveillance
  • Drug safety
  • Clinical development

Learning objectives

At the conclusion of this webinar, participants should be able to:

  • Gain comprehensive insight into cardiovascular risk assessment for oncology drug development
  • Learn best practices and regulatory considerations for developing successful Cardio-Oncology clinical studies
  • Understand innovative, multimodal approaches for monitoring cardiac dysfunction in clinical trails
  • Explore optimal cardiac safety study design and strategies from a case study involving an FDA approved oncology drug

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.